D e s i g n
Randomized (allocation concealed*), blinded (patients, parents, and investigators),* placebo-controlled trial with 28-day follow-up.
S e t t i n g 5 health centers in the Gambia (1 in a semiurban coastal area and 4 in the rural inland region). P a t i e n t s 600 children who were < 10 years of age (mean age 5 y, 52% boys), weighed > 5 kg, were infected with P. falciparum at a density of ≥ 500/µL, had a history of fever, and lived within 20 km of a trial center. Exclusion criteria were requirement for parenteral treatment, treatment within the previous 2 weeks with PS, a hematocrit level < 15%, or evidence of chronic disease. Follow-up was 95% at 14 days and 94% at 28 days.
I n t e r v e n t i o n
Children were allocated to 1 of 3 groups: PS plus placebo (n = 200); PS plus 1 dose of artesunate, 4 mg/kg of body weight (n = 200); or PS plus artesunate, 4 mg/kg daily for 3 days (n = 200). Children received one half of a tablet of PS if their body weight was < 10 kg and an additional one quarter of a tablet for every 5-kg increment.
M a i n o u t c o m e m e a s u r e s
Tolerability, safety, and treatment failure (if rescue treatment was required or the patient was parasitemic) at 14 days and 28 days.
M a i n r e s u l t s
No severe adverse reactions attributable to treatment occurred. Fewer children in the 3-dose-artesunate group than in the PSalone group needed rescue treatment or were parasitemic at 28 days {P < 0.02} † (Table) . No differences in treatment failure existed between the 2 artesunate groups and the PS-alone group at 14 days or between the 1-dose-artesunate and PSalone groups at 28 days (Table) .
C o n c l u s i o n
In Gambian children with acute uncomplicated malaria, pyrimethamine-sulfadoxine and 3 doses of artesunate led to fewer treatment failures at 28 days than did pyrimethamine-sulfadoxine alone. 
C o m m e n t a r y
Chloroquine and PS are the most widely used antimalarial agents in sub-Saharan Africa, but resistance to these drugs is emerging. If a health care catastrophe is to be avoided, alternative therapies are urgently needed. In southeastern Asia, combination therapy with artesunate has been shown to improve the therapeutic efficacy of mefloquine (1) and may slow the emergence of drug resistance (2) . Von Seidlein and colleagues are the first to study a combination regimen of artesunate with PS.
Although the trial was carried out in an area where PS still has good efficacy, the addition of 3 doses of artesunate resulted in a substantially faster therapeutic response and higher cure rate at day 28. Patients who received artesunate (1 or 3 doses) were also less likely to carry gametocytes (the sexual stage of the parasite) during recovery than were those treated with PS alone (23% vs 67% at 7 d). The introduction of atermisinin derivatives in combination with PS may therefore decrease P. falciparum transmission.
The fact that artesunate plus PS was well tolerated and highly efficacious and resulted in reduced gametocyte carriage supports the growing opinion that antimalarial drugs should no longer be used alone but only in combination with an artemisinin derivative (3). The results of further studies combining artesunate with other antimalarial drugs are awaited.
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